SynthesisPloS one2020

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.

Kevin Bowrin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.